The antibody-based technologies team develops novel therapies to treat inflammatory diseases such as heart attack, diabetes and cancer. Our approach begins by investigating how the human immune system naturally protects privileged indivuduals against inflammatory disease. Then, the mechanistic knowledge from these studies is used to recombinantly engineer an entirely novel class of antibody-based therapeutics. A primary therapeutic target of interest to our group is fibroblast activation Protein (FAP). FAP is a serine protease that contributes to type 2 diabetes, liver disease and thrombosis. By investigating the response of the human immune system to FAP, first-in-class FAP inhibiting antibodies have been discovered with unexpected biomolecular modes of action. We now aim to develop these anti-FAP antibodies into novel therapies to treat FAP-related diseases.